BOLT vs OKTA · rev $7.7M vs P/E 84, rev $1.57B
Bolt Biotherapeutics (BOLT) versus Okta Inc (OKTA) — a side-by-side from cached financials, not a winner call.
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on US.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
Latest reported BOLT revenue for 2024-12-31 was $7.7M. Net income was -$63.1M. Revenue was down 2.4% from 2023-12-31 to 2024-12-31. BOLT currently screens at market cap $11.3M.
Latest reported OKTA revenue for 2026-07-31 was $1.57B. Net income was $190.0M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
BOLT currently screens at market cap $11.3M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Not investment advice. Open the BOLT and OKTA stock pages for the full models.
Not investment advice.